It is known that there are close relationships between bone destruction and tumor growth in bone metastasis. RANKL is a central factor in bone metastasis, inducing osteoclastogenesis mediated by its ...
The receptor activator of nuclear factor-κB ligand (RANKL) and its receptor RANK constitute a central axis in the regulation of bone remodelling and metastatic spread. In healthy bone, RANKL produced ...
A potential new therapeutic option for the treatment of nonmuscle invasive bladder cancer: Combination of intravesical oncotherad immunotherapy and platelet rich plasma (PRP). This is an ASCO Meeting ...
The discovery of osteoprotegerin, receptor activator of nuclear factor kappa B (RANK) and RANK ligand as critical molecular determinants of osteoclastogenesis and regulators of bone resorption, has ...
image: Researchers from IDIBELL have shown that pharmacological and genetic inhibition of RANK/RANKL signaling pathway leads to a significant reduction in recurrences and metastases in breast cancer ...
3 Centre for Sport & Exercise Medicine, William Harvey Research Institute, Queen Mary, University of London-John King Centre for Leg Pain, London Independent Hospital, London 4 Centre for Sport & ...
The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in ...
An evaluation of bone marrow stromal-derived growth factor-1 and interleukin-8 levels in patients with stage I-III breast cancer with disseminated tumor cells. This is an ASCO Meeting Abstract from ...
Future Oncol. 2013;9(11):1609-1622. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results